Autor(es): Fernandes, Mónica Alexandra Teotónio
Data: 2015
Identificador Persistente: http://hdl.handle.net/10400.1/8849
Origem: Sapientia - Universidade do Algarve
Projeto/bolsa: info:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBD%2F75137%2F2010/PT;
Assunto(s): Leucemia linfoblástica aguda de linfócitos T; Modelo murino transgénico TEL-JAK2; Timo; Microambiente tumoral; Recetor da linfotoxina beta; Fator nuclear κB; Domínio/Área Científica::Ciências Médicas::Biotecnologia Médica
Tese de doutoramento, Ciências Biomédicas, Departamento de Ciências Biomédicas e Medicina, Universidade do Algarve, 2015
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematopoietic malignancy that arises from the combination of genetic and epigenetic alterations in thymic T-cell precursors and extracellular signals provided by the microenvironment. It was previously found that RelB expression in non-hematopoietic stromal cells promoted T-cell leukemogenesis in the EμSRalpha-TEL-JAK2 transgenic (TJ2-Tg) mouse model. In thymic stromal cells, RelB is a transcription mediator of lymphotoxin-beta receptor (LTβR). Lymphotoxin-mediated activation of LTβR has been implicated in physiological crosstalk between T cells and lymphoid organ stromal cells, but also pathological processes, including carcinogenesis. Since its role in T-ALL has remained elusive, we aimed to determine whether LTβR signaling is activated and playing a role in TEL-JAK2-induced leukemogenesis. In TJ2-Tg thymic lymphomas, activation of LTα1β2-LTβR signaling axis was supported by LTβRencoding gene expression, while the genes encoding its cognate ligand, lymphotoxin (LT)-α and LTβ, were found to be expressed by leukemic T cells, in an NF-κB-dependent manner. LTα1β2 protein was detected at the surface of TJ2-Tg leukemic cells only upon ex vivo culture or mitogenic stimulation. Moreover, we found that cell-surface LTα1β2 is downmodulated in vivo, indicating ongoing signaling. Further supporting a role for lymphotoxin signaling, LTβR genetic deficiency delayed TEL-JAK2-induced leukemia onset, but the tumor load in lymphoid organs and leukemia cell surface phenotype were comparable in end-stage disease. In accordance, the detection of reduced proportions of malignant thymocytes in TJ2-Tg;Ltbr-/- mice with no signs of disease implicated LTβR in early stages of leukemia development. Together, these data indicate that T-ALL-derived lymphotoxin activates LTβR signaling in thymic stromal cells, promoting leukemogenesis. Importantly, lymphotoxin-encoding genes were expressed in T-ALL patient samples, indicating that these may be also involved in human disease. Thus, future studies should provide a better understanding on how cellular crosstalk mediated by the lymphotoxin-LTβR axis supports T-ALL and assess the utility of blocking LTβR signaling as a novel therapeutic approach.
